Pyxis Oncology, Inc.
PYXS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.09 | 0.06 | 0.02 | -0.01 |
| FCF Yield | -9.57% | -25.35% | -37.67% | -20.37% |
| EV / EBITDA | -6.35 | -4.00 | -2.92 | -5.14 |
| Quality | ||||
| ROIC | -26.71% | -18.73% | -18.64% | -26.80% |
| Gross Margin | 0.00% | 100.00% | 0.00% | 50.00% |
| Cash Conversion Ratio | 0.60 | 0.94 | 1.07 | 0.54 |
| Growth | ||||
| Revenue 3-Year CAGR | 1,412,707.64% | 1,412,707.64% | -100.00% | 2,527,383.42% |
| Free Cash Flow Growth | 23.04% | 23.39% | -16.82% | -31.54% |
| Safety | ||||
| Net Debt / EBITDA | -0.43 | -0.45 | -0.31 | -0.04 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -1,487.58 | -464.02 | -257.09 |